Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | RYR2 | Q92736 | 3/20 | 0.32 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167756 | 0.91 | SLC6A4 (0.52) | SLC6A4SLC6A2MCHR1HTR2CRYR2 | |
| SCHEMBL7213331 | 0.81 | SLC6A4 (0.54) | SLC6A4SLC6A2MEN1KMT2AATM | |
| SCHEMBL6152065 | 0.77 | SLC6A4 (0.47) | SLC6A4SLC6A2MEN1KMT2AATM | |
| SCHEMBL6151977 | 0.76 | SLC6A4 (0.40) | SLC6A4SLC6A2MEN1KMT2ATTR | |
| SCHEMBL15862233 | 0.75 | HTR2C (0.41) | SLC6A4MCHR1MEN1KMT2AATM | |
| SCHEMBL6152060 | 0.74 | SLC6A4 (0.40) | SLC6A4SLC6A2MEN1KMT2AATM | |
| SCHEMBL27811149 | 0.74 | HTR2C (0.39) | SLC6A4MCHR1MEN1KMT2AHTR2C | |
| SCHEMBL25569841 | 0.71 | SLC6A4 (0.33) | SLC6A4MCHR1MEN1KMT2A | |
| SCHEMBL7130346 | 0.71 | SLC6A4 (0.52) | SLC6A4SLC6A2 | |
| SCHEMBL7207167 | 0.69 | SLC6A4 (0.69) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | SLC6A4 5/4885SLC6A2 9/4885MCHR1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.